Retatrutide 30mg

Description

Retatrutide 30 mg provides a high-concentration research format of the triple-agonist peptide Retatrutide. Recommended for laboratory settings conducting long-term or higher-volume studies.

Research Profile

• Triple-agonist activity across GIP, GLP-1, and glucagon receptors
• Studied in metabolic and energy-balance research models
• High-concentration format for extended studies
• QC verified by HPLC and mass spectrometry

Specifications

• Compound: Retatrutide (LY3437943)
• Dosage: 30 mg per vial
• Purity: ≥ 98% (HPLC)
• Form: Lyophilized powder
• Storage: 2–8 °C (lyophilized); –20 °C (reconstituted)

For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.